Symbols

ABCL

AbCellera Biologics·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 2

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ABCL

Abcellera Biologics Inc.

A Canadian provider of drug discovery platform that designed to develop next-generation antibody therapies

Industry

Biological Technology

Established Date

11/08/2012

Listing Date

12/11/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

562

Fiscal Year Ends

12-31

Website

www.abcellera.com

Security Type

Common stock

Office address

150 W 4th Avenue, Vancouver, BC V5Y 1G6

Business

Introduction

AbCellera Biologics Inc., was incorporated and commenced business activities on November 8, 2012 under the British Columbia Business Companies Act. The company is a clinical-stage biotechnology company focused on discovering and developing best-in-class antibody drugs for high unmet medical needs. The company has established a platform to advance antibody drug projects, which they believe provides them with a competitive advantage in addressing challenging high-value targets such as complex transmembrane proteins and new models including multispecific and antibody-drug conjugates.

Company Financials

EPS

ABCL has released its 2025 Q4 earnings. EPS was reported at -0.03, versus the expected -0.18, beating expectations. The chart below visualizes how ABCL has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ABCL has released its 2025 Q4 earnings report, with revenue of 44.85M, reflecting a YoY change of 788.18%, and net profit of -8.95M, showing a YoY change of 73.85%. The Sankey diagram below clearly presents ABCL's revenue sources and cost distribution.